Edgewise Therapeutics Inc (EWTX) FinancialsEWTXEdgewise Therapeutics Inc

Evaluating the bottom line, Edgewise Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.03%, provide a clear picture of how effectively EWTX converts its operational activities into shareholder value.

In the context of the broader market, EWTX competes directly with industry leaders such as DYN and ELVN. With a market capitalization of $4.80B, it holds a leading position in the sector. When comparing efficiency, EWTX's gross margin of N/A stands against DYN's N/A and ELVN's N/A. Such benchmarking helps identify whether Edgewise Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Edgewise has shown significant volatility in its earnings, with a consistent negative EPS over the past quarters, culminating in a Q2 EPS of -$0.53. The company has a current ratio of 16.24, indicating strong liquidity, but ongoing losses raise concerns about sustainability.